Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Hemophilia Market Size From 2025 to 2034?
The size of the hemophilia market has experienced significant growth in the past few years. An expansion from $13.83 billion in 2024 to $14.98 billion in 2025 is anticipated, indicating a compound annual growth rate (CAGR) of 8.3%. Factors contributing to the growth during the historical period include government strategies, a rising count of hemophilia patients, escalated diagnostic screenings, and heightened awareness surrounding hemophilia therapies.
The market for hemophilia is projected to witness substantial expansion in the upcoming years, hitting a size of$20.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. This projected expansion during the forecast period can be ascribed to factors such as advancing research and development in hemophilia, increased diagnostic screenings, a surge in healthcare expenditures, and worldwide treatment accessibility. Key projected trends for the forecast span involve the launching and approval of novel drugs, an escalation in drug development, extensive research and clinical trials, the rise of digital health solutions, and advancements in treatment choices.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12905&type=smp
What are the Fundamental Drivers and Innovations Shaping the Hemophilia Market?
The growth of the hemophilia market is anticipated to be driven by the increasing prevalence of genetic abnormalities. Genetic abnormalities, also identified as genetic mutations or genetic disorders, are changes in an individual’s genetic code that can lead to various health issues and physical characteristics. The goal of hemophilia treatment is to prevent or manage bleeding events, limit complications, and enhance the life quality of those with such genetic disorders. For example, as reported by Gene People, a registered charity organization in the UK devoted to genetic conditions, in June 2023, one out of 25 kids was diagnosed with a genetic disorder. This results in 30,000 infants and young children in the UK, along with over 2.4 million children and adults upshot by a genetic disorder annually. Hence, the increasing prevalence of genetic abnormalities is positively influencing the hemophilia market’s growth.
How Is the Hemophilia Market Segmented?
The hemophiliamarket covered in this report is segmented –
1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users
Subsegments:
1) By Hemophilia A: Severe Hemophilia A; Moderate Hemophilia A; Mild Hemophilia A
2) By Hemophilia B: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
3) By Hemophilia C: Severe Hemophilia C; Mild Hemophilia C
4) By Other Types: Acquired Hemophilia; Von Willebrand Disease
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12905&type=smp
Which Regions Are Driving the Next Phase of the Hemophilia Market Growth?
North America was the largest region in the hemophilia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Hemophilia Market?
Leading companies in the hemophilia market are pioneering new drugs such as ALTUVIIIO to maintain their market position. For example, in February 2023, Sanofi S.A, a French pharmaceutical and healthcare corporation, introduced ALTUVIIIO for hemophilia, which received approval from the US government entity, The Food and Drug Administration (FDA). ALTUVIIIO, which is to be taken once a week, is the inaugural and sole hemophilia A treatment that brings regular to nearly normal factor activity levels (over 40%) for the majority of the week and significantly reduces bleeding compared to the previous factor VIII prophylaxis.
View the full report here:
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report
How Is the Hemophilia Market Defined and What Are Its Core Parameters?
Hemophilia is a rare genetic disorder that affects the body’s ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12905
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model